Highlights
- 1
- 2Seminars in respiratory and critical care medicine · 2024
- 3
Publications
367 publications
Clinical research
7 studies
Completed & closed trials (7)
- PINCT06872892A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)PHASE3 · Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · CLOSED TO ACCRUAL (as of 2026)Bronchiectasis
- PINCT05238675A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study Evaluating Efficacy, Safety and Tolerability of BI 1291583 qd Over at Least 24 Weeks in Patients With Bronchiectasis (AirleafTM)PHASE2 · Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · IRB STUDY CLOSURE (as of 2024)Bronchiectasis
- PIIndividual Patient Expanded Access Investigational New Drug Application (IND), Clofazimine. sIND# 159602Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
- PIIndividual Patient Expanded Access Investigational New Drug Application (IND), Clofazimine. sIND# 161452Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
- PIDynamic assessment of immune system in COVID-19 patients: _x000D_ Flu Vaccine Pilot Study 1University of Connecticut · IRB STUDY CLOSURE (as of 2021)
- PIIndividual Patient Expanded Access Investigational New Drug Application (IND), Clofazimine. sIND# 155956Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2021)
- PIIndividual Patient Expanded Access Investigational New Drug Application (IND), Clofazimine. sIND# 154603Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2021)
Media highlights
1 clip
- Why You Shouldn’t Tough Out Pneumonia SymptomsMen's Health · August 19, 2026